Celldex Therapeutics CLDX D&A

D&A at other companies

Eli LillyLLY

$534M+11.7%

PfizerPFE

$1.61B-0.3%

Rogers CorporationROG

$13.2M-5.0%

AmgenAMGN

$1.11B-17.1%

Regeneron PharmaceuticalsREGN

$123.7M-8.4%

IncyteINCY

$26.48M+15.5%

FAQ

What is Celldex Therapeutics's D&A?

Celldex Therapeutics (CLDX) reported D&A of $902K in Q2 2026.

How has Celldex Therapeutics's D&A changed year-over-year?

Celldex Therapeutics's D&A increased by 3.3% year-over-year, from $873K to $902K.

What is the long-term trend for Celldex Therapeutics's D&A?

Over 4 years (2021 to 2025), Celldex Therapeutics's D&A has grown at a 2.5% compound annual growth rate (CAGR), from $3.07M to $3.38M.

What does D&A mean?

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.